Clinical studies
Tomorrow's therapies come from today's studies!
We offer a wide range of services from early clinical trials (phase I, first-in-human) to large randomized phase III trials, as well as phase IV and registry studies. We are currently conducting more than 70 clinical trials in oncology, of which an average of 30 are actively recruiting studies. The portfolio includes trials for all solid tumors and lymphomas, in both early and advanced tumor stages.
The team, headed by Prof. Heinz Läubli, Dr. David König and Céline Jenni, comprises 12 employees and is part of the Oncology Department at the University Hospital Basel. This gives patients access to new therapeutic approaches in order to achieve optimal oncological treatment.
If you, as a referring physician or patient, have any questions about a study or possible participation in a study, please contact the relevant contact person by e-mail.
Brain tumors
Glioblastoma
First line
GLUGLIO
A phase IB/II study of glutamate signaling inhibitors in combination with chemoradiotherapy in patients with newly diagnosed glioblastoma.
Contact: Prof. Heinz Läubli
GLIOSUN
A study to evaluate the safety and efficacy of the anti-tumor human antibody cytokine fusion protein L19TNF in combination with standard chemoradiotherapy with temozolomide in patients with newly diagnosed glioblastoma.
Contact: Dr. Benjamin Thiele
EF-41
A phase III study of Optune® (TTFields, 200 kHz) in combination with temozolomide and pembrolizumab compared to Optune® in combination with temozolomide and placebo for the treatment of newly diagnosed glioblastoma.
Contact: Dr. Benjamin Thiele
Gliofocus
A phase III trial comparing niraparib and temozolomide in patients with newly diagnosed MGMT-unmethylated glioblastoma.
Contact: Dr. Benjamin Thiele
Recurrent
PHENIX
A phase II study to investigate the safety and efficacy of trimipramine in combination with bevacizumab and atezolizumab in patients with recurrent glioblastoma.
Contact: Dr. Benjamin Thiele
Head and neck tumors
First line
JADE
A phase III study to evaluate dostarlimab as sequential therapy after chemoradiotherapy in patients with locally advanced, non-surgical squamous cell carcinoma of the head and neck.
Contact: PD Dr. Anna Brandt
Lung tumors
Small cell lung cancer (SCLC)
Advanced stage first line
AMGEN 20240178
A phase III study of first-line treatment with tarlatamab in combination with durvalumab, carboplatin and etoposide compared with durvalumab, carboplatin and etoposide in untreated advanced-stage small cell lung cancer (DeLLphi-312).
Contact: Dr. Andreas Schmitt
ETOP 23-22 RAISE
A phase II study to investigate the effect of niraparib and immunotherapy in patients with SLFN11-positive small cell lung cancer.
Contact: Dr. Andreas Schmitt
Advanced stage second line
GSK EMBOLD
A phase III study of GSK5764227, a B7-H3 antibody-drug conjugate (ADC), compared to topotecan in patients with relapsed small cell lung cancer (SCLC).
Contact: Dr. Andreas Schmitt
Non-small cell lung cancer (NSCLC)
Early and locally advanced stage
ETOP 27-23 ARCH
A phase III study of adjuvant treatment with cemiplimab in patients with stage II-IIIA NSCLC who have undergone surgery and have not previously received adjuvant chemotherapy.
Contact: Dr. Judith Hafer
ETOP 25-23 ADOPT
A phase III study to evaluate the benefit of adjuvant durvalumab treatment after neoadjuvant chemotherapy plus durvalumab in patients with operable stage IIB-IIIB (N2) non-small cell lung cancer.
Contact: Dr. Andreas Schmitt
PACIFIC-8
A phase III study of durvalumab in combination with domvanalimab versus durvalumab and placebo in patients with locally advanced (stage III), inoperable non-small cell lung cancer whose disease has not progressed after definitive platinum-based radiochemotherapy.
Contact: Dr. Benjamin Thiele
Advanced stage first line
TROPION-Lung 08
A phase III study of Dato-DXd plus pembrolizumab versus pembrolizumab alone in untreated study participants with advanced or metastatic non-small cell lung cancer with high PD-L1 levels (≥ 50%), without targetable genomic alterations.
Contact: Dr. Benjamin Thiele
Krascendo 170 Lung
A Phase IB/II study to evaluate the safety and efficacy of divarasib at various doses in combination with other cancer therapies in patients with previously untreated advanced or metastatic non-small cell lung cancer with a KRASG12C mutation.
Contact: Dr. Andreas Schmitt
Krascendo 2
A phase III study to evaluate the efficacy and safety of divarasib with pembrolizumab compared to pembrolizumab/pemetrexed/carboplatin in patients with previously untreated advanced or metastatic non-squamous non-small cell lung cancer with a KRASG12C mutation.
Contact: Dr. Andreas Schmitt
CTL-002-003
A phase II study to evaluate the efficacy and safety of visugromab compared to placebo in combination with pembrolizumab, pemetrexed and carboplatin in the first-line treatment of participants with metastatic non-squamous non-small cell lung cancer.
Contact: Dr. Benjamin Thiele
Fiber-Boost
A study investigating the effects of a high-fiber diet on the immunotherapy of advanced lung cancer and its effects on the gut microbiome and the immune system.
Contact: Prof. Heinz Läubli
Advanced stage second and further lines
CTL-002-004
A phase II placebo-controlled study to evaluate the efficacy and safety of visugromab and nivolumab with or without docetaxel compared to docetaxel alone in the second-line treatment of patients with metastatic non-small cell lung cancer.
Contact: Dr. Benjamin Thiele
RASolve
A phase III study of daraxonrasib versus docetaxel in patients with previously treated locally advanced or metastatic RAS-mutated non-small cell lung cancer.
Contact: PD Dr. Benjamin Kasenda
BaseTIL-02
A phase II trial of adoptive cell therapy with tumor-infiltrating lymphocytes in patients with non-small cell lung cancer.
Contact: Prof. Heinz Läubli
Lymphomas (non-Hodgkin's)
Relapsed/refractory
NX-5948-301
A phase I study to evaluate the safety and efficacy of NX-5948, a Bruton's tyrosine kinase (BTK) degrader, in patients with relapsed/refractory B-cell malignancies.
Contact: PD Dr. Benjamin Kasenda
CA123-1000
A Phase I/II study of BMS-986458 alone or in combination with anti-lymphoma agents in relapsed/refractory non-Hodgkin lymphoma.
Contact: Dr. Fatime Krasniqi
Melanomas
TIL therapy (here the treatment does not take place within a study but via a temporary authorization)
An adoptive cell therapy with tumor-infiltrating lymphocytes and interleukin-2 in patients with advanced melanoma.
Contact: Prof. Heinz Läubli
Mesothelioma
Sarcomas
First line
SAKK 57/24
Feasibility of overall neoadjuvant treatment with hyperthermia in patients with high-risk soft tissue sarcomas of the extremities and trunk.
Contact: Dr. Fatime Krasniqi
Gastrointestinal tumors
Urogenital tumors
Prostate cancer
MK2400-001
A phase III trial comparing ifinatamab deruxtecan with docetaxel in participants with metastatic castration-resistant prostate cancer (mCRPC).
Contact: Prof. Frank Stenner
ProBio
An outcome-adaptive study with biomarkers in patients with metastatic prostate cancer.
Contact: Prof. Frank Stenner
Various tumors / Phase I studies
DODEKA
A Phase I study to assess the safety and early signs of efficacy of the human monoclonal antibody-cytokine fusion protein IL12-L19L19.
Contact: Prof. Heinz Läubli
ISCA-CHECK
Safety and modulation of adaptive immunity by Iscador® Qu Viscum Album extract in patients with advanced, recurrent or metastatic cancer treated with immune checkpoint inhibitors.
Contact: PD Dr. Benjamin Kasenda